The company is substantially advanced the course of the new solution for ATTR-CM, utilizing the investigational drug. Early patient data suggests significant outcomes for individuals diagnosed from this debilitating https://attr-cm947817.ka-blogs.com/95682350/bridgebio-progresses-amyloidosis-therapy-through-the-therapy